NIH Licenses New Antibody to Spot Immune Cell Proteins
Published Date: 6/1/2026
Notice
Summary
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Antibody 18H2 Available For Licensing
The NIH/NIAID has made monoclonal antibody 18H2 (HHS Ref. No. E-104-2025-0) available for licensing for commercial development under 35 U.S.C. 209 and 37 CFR part 404. If you are a company or research group, you can contact Yogikala Prabhu (tel. 202-365-4785 or [email protected]) to inquire about licensing.
Collaborative Research Opportunities Offered
NIAID is actively seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize 18H2, including use in pre-clinical models, diagnostic assay development, and high-throughput screening. Interested parties should contact Yogikala Prabhu at 202-365-4785 or [email protected].
Enables Development of Diagnostic Tests
The 18H2 antibody can be used to develop tests that track regulatory T cell (Treg) function and Eos protein levels in patients to monitor autoimmune diseases, cancer treatments, and organ transplants. Companies and labs could use this technology to build diagnostic assays and immune-monitoring tools.
Technology Is at Pre-Clinical Stage
The 18H2 antibody is described as being at the 'Pre-Clinical' development stage. That means the technology has been validated in laboratory settings but has not yet reached clinical trials or market-ready status.
Confidential Disclosure Agreement Required
A signed Confidential Disclosure Agreement (CDA) is required to receive copies of unpublished information related to the 18H2 invention. Parties must sign the CDA before NIH/NIAID will provide unpublished technical details.
Foreign Patent Filings May Extend Coverage
The notice states that foreign patent applications are filed on selected inventions to extend market coverage and may also be available for licensing. This can affect the geographic scope of licensing rights for 18H2.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
Previous / Next Documents
Previous: 2026-10811, National Eye Institute; Notice of Closed Meeting
The National Eye Institute’s advisory council is holding a private virtual meeting on July 17, 2026, to review and decide on grant applications. This meeting affects researchers seeking funding for eye-related projects and keeps sensitive info safe. No money changes are announced yet, but the decisions could impact future research support.
Next: 2026-10814, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.